Updates are available Correction dated 2020-07-22
Click to view Correction: https://doi.org/10.1007/s00330-020-07073-4
-
Authors
Chang, Gary H.
Felson, David T.
Qiu, Shangran
Guermazi, Ali
Capellini, Terence D.
Kolachalama, Vijaya B. http://orcid.org/0000-0002-5312-8644
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR070139, 1R01AR070139, 1R01AR070139)
American Heart Association (17SDG33670323)
National Center for Advancing Translational Sciences (1UL1TR001430, 1UL1TR001430)
- License Information
-
More Information
Article History
Received: 20 November 2019
Revised: 2 January 2020
Accepted: 15 January 2020
First Online: 13 February 2020
Change Date: 22 July 2020
Change Type: Correction
Change Details: The original version of this article, published on 13 February 2020, unfortunately contained a mistake.
Compliance with ethical standards
:
: The scientific guarantor of this publication is Dr. David Felson (dfelson@bu.edu).
: Ali Guermazi is shareholder of BICL and consultant to Pfizer, AstraZeneca, TissueGene, Roche, Galapagos, and MerckSerono.
: No complex statistical methods were necessary for this paper. Additionally, Dr. Kolachalama has needed statistical expertise.
: Written informed consent was not required for this study because de-identified data is publicly available (Osteoarthritis Initiative: ExternalRef removed). At the time of enrollment, informed consent and ethical committee approvals were obtained by the OAI investigators.
: Institutional Review Board approval was not required because the data was obtained from a public database (Osteoarthritis Initiative: ExternalRef removed).
: The cohort has been reported in ExternalRef removed.
: • This is a case-control study.
